Analysts Set Caris Life Sciences, Inc. (NASDAQ:CAI) Target Price at $28.86

Caris Life Sciences, Inc. (NASDAQ:CAI) has been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $28.8571.

A number of equities research analysts have weighed in on CAI shares. The Goldman Sachs Group started coverage on shares of Caris Life Sciences in a report on Wednesday, April 1st. They issued a “buy” rating and a $27.00 price target for the company. Piper Sandler started coverage on shares of Caris Life Sciences in a report on Friday, April 10th. They issued a “neutral” rating and a $21.00 price target for the company. Canaccord Genuity Group cut their price target on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating for the company in a report on Friday, March 13th. Evercore set a $38.00 price target on shares of Caris Life Sciences in a report on Monday, January 5th. Finally, Robert W. Baird upped their price target on shares of Caris Life Sciences from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, February 27th.

Institutional Investors Weigh In On Caris Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of CAI. T. Rowe Price Investment Management Inc. lifted its stake in Caris Life Sciences by 14.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock valued at $248,377,000 after buying an additional 1,180,200 shares in the last quarter. Braidwell LP lifted its stake in Caris Life Sciences by 6.8% during the fourth quarter. Braidwell LP now owns 7,816,142 shares of the company’s stock valued at $210,880,000 after buying an additional 500,000 shares in the last quarter. PointState Capital LP lifted its stake in Caris Life Sciences by 73.0% during the fourth quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock valued at $181,271,000 after buying an additional 2,834,986 shares in the last quarter. Orbimed Advisors LLC lifted its stake in Caris Life Sciences by 2.7% during the fourth quarter. Orbimed Advisors LLC now owns 3,116,011 shares of the company’s stock valued at $84,070,000 after buying an additional 81,153 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Caris Life Sciences by 185.0% in the 4th quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock worth $65,974,000 after purchasing an additional 1,587,176 shares during the period.

Caris Life Sciences Stock Down 2.8%

CAI stock opened at $18.47 on Friday. The firm has a market capitalization of $5.22 billion and a P/E ratio of -102.61. The business has a 50-day moving average of $19.10. Caris Life Sciences has a fifty-two week low of $16.28 and a fifty-two week high of $42.50. The company has a quick ratio of 7.35, a current ratio of 7.85 and a debt-to-equity ratio of 0.66.

Caris Life Sciences (NASDAQ:CAI) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to analyst estimates of $281.00 million. During the same period in the previous year, the company earned ($1.73) EPS. The business’s revenue for the quarter was up 125.4% compared to the same quarter last year. Equities analysts anticipate that Caris Life Sciences will post 0.12 EPS for the current year.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.